Estrella Immunopharma, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
ESLA$0.75+45.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Operations
| For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 | |
|---|---|---|---|---|
| Operating expenses | ||||
| Research and development (including $1,375,000, $4,625,000, $2,750,000 and $6,000,000 from a related party for the three months ended June 30, 2026 and 2025 and the six months ended June 30, 2026 and 2025, respectively) | $1,400,232 | $4,660,301 | $2,800,507 | $6,070,489 |
| General and administrative (including $63,231, $65,151, $133,177 and $129,586 from related parties for the three months ended June 30, 2026 and 2025 and the six months ended June 30, 2026 and 2025, respectively) | 684,015 | 883,727 | 1,467,177 | 1,577,837 |
| Total operating expenses | 2,084,247 | 5,544,028 | 4,267,684 | 7,648,326 |
| Loss from Operations | (2,084,247) | (5,544,028) | (4,267,684) | (7,648,326) |
| Other expenses: | ||||
| Change in fair value of derivative liabilities | (222,092) | - | (330,719) | - |
| Total other expenses | (222,092) | - | (330,719) | - |
| Loss before income tax | (2,306,339) | (5,544,028) | (4,598,403) | (7,648,326) |
| Income tax provision | - | (850) | - | (863) |
| Net loss | $(2,306,339) | $(5,544,878) | $(4,598,403) | $(7,649,189) |
| Net loss applicable to common stock per share, basic and diluted | $(0.05) | $(0.15) | $(0.11) | $(0.21) |
| Weighted average common stock outstanding, basic and diluted | 42,997,733 | 36,165,589 | 42,561,826 | 36,176,878 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.